Study of the Biological Mechanisms Associated With the Immunogenicity in Anaplastic Large Cell Lymphoma ( ALCL ) ALK +

ALCL Clinical Trial

— Immuno ALCL  

Official title:

Study of the Biological Mechanisms Associated With the Immunogenicity in Anaplastic Large Cell Lymphoma ( ALCL ) ALK +

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02902874
• Other study ID #: 2009-A01343-54
• Secondary ID: 2009/1603
• Status: Completed
• Phase: N/A
• Start date: April 21, 2010
• Est. completion date: December 31, 2020

Study information

• Verified date: May 2022
• Source: Gustave Roussy, Cancer Campus, Grand Paris
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To study the correlation between the polymorphism of the main immunity genes and progression-free survival in ALCL of the child.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 185
• Est. completion date: December 31, 2020
• Est. primary completion date: December 31, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Every patients treated according to COPAD-IGR, HM 89,91 and 97 and ALCL99 protocols and included in related studies

• Clinical data registered in SFCE database

• Signed consent form

Exclusion Criteria:

• No ALK expression on tumour

• No consent signed

Related Conditions & MeSH terms

• ALCL
• Lymphoma, Large-Cell, Anaplastic

Intervention

Other:
• Blood sample

Locations

Country	Name	City	State
France	Gustave Roussy	Villejuif	Val De Marne

Sponsors (1)

Lead Sponsor	Collaborator
Gustave Roussy, Cancer Campus, Grand Paris

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of single nucleotide polymorphisms in main immunogenicity genes using VERACODE ILLUMINA technology		up to 78 months